Nexus Pharmaceuticals, LLC announces the launch of Tacrolimus Injection, USP 5 mg/mL. This launch signifies the first and only Tacrolimus vial-format solution for healthcare providers and transplant ...

Please provide your email address to receive an email when new articles are posted on . Tacrolimus alone had a dose-response relationship with achieving complete renal response in SLE. Combination ...

Please provide your email address to receive an email when new articles are posted on . The tacrolimus group had a 1.86-fold higher rate of relapse-free survival vs. those assigned mycophenolate ...

Tacrolimus Injection is a crucial immunosuppressant indicated for the prophylaxis of organ rejection in patients receiving liver or kidney transplants. “We are pleased to share the launch of Nexus’ ...